Twist Bioscience Corporation experienced strong upward momentum following sustained investor enthusiasm surrounding its recent strategic collaboration with Eli Lilly. Under the data-services agreement, Twist provides high-throughput antibody characterization and wet-lab data directly into Lilly’s AI-driven TuneLab drug discovery platform. The market views this deal as a major validation of Twist’s role as an essential provider of experimental data for machine learning models in drug discovery. By establishing itself as a key biological infrastructure player in the artificial intelligence biopharma stack, Twist has captured heightened buying interest from institutional and momentum-driven investors seeking leveraged exposure to AI drug…